

West Virginia Medicaid Drug Utilization Review Board Minutes February 16, 2022

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
K.C. Lovin, PA-C
Ernest Miller, DO

Members Absent:

C.K. Babcock, PharmD
Michael Ballow, PharmD
Mary Nemeth-Pyles, MSN, RN, CS

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Priya Shah, PharmD, Drug Utilization Review Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Data Analyst
Gail Goodnight, RPh, Rebate Manager

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Rob Stanton, PharmD, MBA, Marshall University
Jon Willis, Marshall University
Eric Sears, RPh, Gainwell
Ryan Fell, PharmD, Change Healthcare
Laureen Biczak, Change Healthcare

I. INTRODUCTIONS

- a. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:05 pm EDT. The DUR Board and others introduced themselves.

II. APPROVAL OF MINUTES FROM November 17th, 2021 DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. **OLD BUSINESS**

Elections were held for the upcoming year. Congratulations to Christopher Terpening, Chair and David Gloss, Vice Chair.

IV. **NEW BUSINESS**

a. **Speakers**

- i. none

b. **Updates from January 26th, 2022 P & T Committee Meeting**

- i. Ryan Fell presented the updates from the January 16, 2022, P & T meeting

c. **Prior Authorization Criteria.** Attachment A

- i. **Hetlioz**: approved as presented
ii. **Opzelura Cream**: approved as presented
iii. **Austedo**: approved as presented
iv. **Xenazine**: approved as presented
v. **Nuzyra**: approved as presented
vi. **Invega Hafyera**: approved as presented
vii. **Ergot alkaloids**: approved as presented
viii. **Lybalvi**: approved as presented
ix. **Kerendia**: approved as presented
x. **Analgesics, Narcotic Long-Acting-Fentanyl**: approved as presented

V. **REPORTS –4th Quarter 2021**

- a. **Gainwell Technologies Quarterly Report:** Mr. Sears presented an overview of the 2021 Fourth Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the Fourth Quarter of 2021. Attachment C
- c. **Marshall University Coalition:** Dr. Stanton reported on the progress of retro DUR, the lock in program and number of letters sent/returned for the Fourth Quarter of 2021. He requested the Board rank the 4 black box warnings for interventions. Attachment D

VI. **OTHER BUSINESS**

KC Lovin shared that she provided a deposition for the State of WV vs. Jansen Pharmaceuticals.

VII. **NEXT MEETING AND ADJOURNMENT**

- VIII. a. The meeting concluded at 5:05 pm EDT.
b. The next meeting will be May 25th, 2022, from 4-6pm on a virtual platform.